Evaluation of Exposure Doses of Elective Nodal Irradiation in Chemoradiotherapy for Advanced Esophageal Cancer
-
- Hiroyasu Tamamura
- Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
-
- Kenkei Hasatani
- Department of Gastroenterology, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
-
- Sae Matsumoto
- Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
-
- Satoko Asahi
- Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
-
- Hitoshi Tatebe
- Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
-
- Yoshitaka Sato
- Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
-
- Keiichiro Matsusita
- Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
-
- Yuji Tameshige
- Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
-
- Yoshikazu Maeda
- Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
-
- Makoto Sasaki
- Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
-
- Shigeyuki Takamatsu
- Department of Radiotherapy, Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, Japan
-
- Kazutaka Yamamoto
- Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui City 910-8526, Fukui Prefecture, Japan
抄録
<jats:p>We evaluated elective nodal irradiation (ENI) doses during radical chemoradiotherapy (CRT) for esophageal cancer (EC). A total of 79 patients (65 men and 14 women) aged 52–80 years with T1-3, N0-3, and M0 (including M1ly) who underwent CRT for EC during November 2012–September 2019 were eligible for this retrospective analysis. Patients were divided into two groups: the high-dose group (HG), including 38 patients who received ≥40 Gy as ENI; and the low-dose group (LG), including 41 patients who received <40 Gy. The median doses were 40.0 and 36.0 Gy in HG and LG, respectively. During the follow-up (median: 36.7 months), no lymph node recurrence was observed in the ENI field in all patients. Lymph node recurrence near the ENI field was observed in six patients. No significant differences were observed between the two groups in median overall survival, progression-free survival, and local control. Grade 3–4 acute and late adverse events were observed in five patients of HG and six patients of LG, respectively. No ulceration or stricture was observed in the ENI field on endoscopy examined with 58 Gy irradiation. In conclusion, an ENI dose of 36 Gy could be considered to control the elective nodes of EC.</jats:p>
収録刊行物
-
- Cancers
-
Cancers 15 (3), 860-, 2023-01-30
MDPI AG